BridgeMD
The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double-blinded, placebo-controlled, phase IV pilot trial (STEMILAND-1)
EU CTIS ID: 2025-523676-23-00
What this study is testing
The primary objective is to evaluate the feasibility of very early continuous i.v. administration of the highly cardioselective betablocker Landiolol in anterior/lateral ST-elevation acute coronary syndrome (STE-ACS).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Anterior or lateral ST-elevation acute coronary syndrome (STE-ACS; defined as ST-segment elevation in two or more of precordial leads V1-V6, and I and aVL, representing anterior wall infarction or ischemia)
- Treated at our study center
- Age >= 18 years
- Hemodynamically stable (MAP >60 mmHg, heart rate > 70/min)
- Oral and written informed consent
You likely can't join if
- Known or suspected pregnancy
- Acute asthma exacerbation
- Severe metabolic acidosis
- Known pathologies of the cardiac electrical conduction system (e.g., sick-sinus-syndrome, AV-block II° or III°)
- Acute heart failure and cardiogenic Shock (Killip Classes III and IV)
- Allergy or insensitivity to ß-blockers
See the full eligibility criteria
- Anterior or lateral ST-elevation acute coronary syndrome (STE-ACS; defined as ST-segment elevation in two or more of precordial leads V1-V6, and I and aVL, representing anterior wall infarction or ischemia)
- Treated at our study center
- Age >= 18 years
- Hemodynamically stable (MAP >60 mmHg, heart rate > 70/min)
- Oral and written informed consent
- Known or suspected pregnancy
- Acute asthma exacerbation
- Severe metabolic acidosis
- Known pathologies of the cardiac electrical conduction system (e.g., sick-sinus-syndrome, AV-block II° or III°)
- Acute heart failure and cardiogenic Shock (Killip Classes III and IV)
- Allergy or insensitivity to ß-blockers
- Known pulmonary hypertension
- Known pheochromocytoma
- Anticipated time to wire-crossing >120 minutes after first medical contact
- Thrombolysis candidate as defined by treating physician
- Heart rate < 50 bpm
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.